Novartis Begins CAR-T Payment Experiments With Outcomes-Based Contract With CMS

 
• By Cathy Kelly
3d illustration of T cells or cancer cells
Novartis's Kymriah will be reimbursed under a groundbreaking arrangement

More from Pricing Debate

More from Market Access